Fresenius Medical Care appoints Shervin J. Korangy as new CEO

Fresenius Medical Care AG has announced a change in leadership, with Shervin J. Korangy appointed as Chairman of the Management Board, effective October 12, 2026. Korangy, who previously served as a member of the company’s Supervisory Board, will resign from that position to assume the CEO role. He succeeds Helen Giza, who will depart the company at the end of October 11, 2026.

The leadership transition follows a period of cost-cutting under the FME25+ program, which reduced the company’s cost base by approximately 1.2 billion euros. While the company noted the transition marks the end of a specific phase, it did not provide specific reasons for Giza’s departure.

Following the announcement, Bernstein Research maintained a ‘Market-Perform’ rating for the company with a price target of 44.65 euros. Analysts noted that while the company’s increased focus on growth is promising, it faces challenges due to a structurally difficult end market for dialysis services.